X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2281) 2281
Publication (157) 157
Book Review (15) 15
Book / eBook (6) 6
Dissertation (2) 2
Book Chapter (1) 1
Data Set (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2211) 2211
female (1433) 1433
male (1378) 1378
index medicus (1232) 1232
middle aged (1206) 1206
oncology (1169) 1169
antimetabolites, antineoplastic - therapeutic use (1145) 1145
aged (1101) 1101
chemotherapy (907) 907
adult (848) 848
antimetabolites, antineoplastic - administration & dosage (826) 826
cancer (807) 807
antimetabolites, antineoplastic - adverse effects (775) 775
treatment outcome (630) 630
deoxycytidine - analogs & derivatives (627) 627
medicine & public health (426) 426
antineoplastic combined chemotherapy protocols - therapeutic use (392) 392
care and treatment (380) 380
aged, 80 and over (367) 367
gemcitabine (351) 351
5-fluorouracil (343) 343
fluorouracil - therapeutic use (330) 330
pharmacology & pharmacy (330) 330
research (323) 323
deoxycytidine - therapeutic use (317) 317
hematology (309) 309
therapy (307) 307
fluorouracil - administration & dosage (306) 306
fluorouracil (293) 293
deoxycytidine - administration & dosage (292) 292
deoxycytidine - adverse effects (266) 266
prognosis (262) 262
capecitabine (256) 256
retrospective studies (254) 254
fluorouracil - adverse effects (250) 250
survival (248) 248
carcinoma (233) 233
antimetabolites, antineoplastic - pharmacology (226) 226
adenocarcinoma - drug therapy (217) 217
surgery (207) 207
survival analysis (205) 205
drug therapy (202) 202
drug administration schedule (198) 198
disease-free survival (197) 197
metastasis (191) 191
antineoplastic agents (190) 190
neoplasm staging (190) 190
colorectal cancer (189) 189
pancreatic neoplasms - drug therapy (189) 189
toxicity (189) 189
fluorouracil - analogs & derivatives (187) 187
follow-up studies (186) 186
survival rate (185) 185
health aspects (184) 184
analysis (182) 182
methotrexate (182) 182
trial (180) 180
cancer research (179) 179
antineoplastic combined chemotherapy protocols - adverse effects (177) 177
dosage and administration (176) 176
risk factors (176) 176
radiotherapy (174) 174
drug combinations (173) 173
pancreatic cancer (173) 173
tumors (173) 173
antimitotic agents (172) 172
combined modality therapy (171) 171
pharmacology/toxicology (171) 171
hematology, oncology and palliative medicine (165) 165
animals (162) 162
clinical trials (156) 156
adolescent (153) 153
leukemia (153) 153
cisplatin (152) 152
chemotherapy, adjuvant (147) 147
patients (142) 142
colorectal neoplasms - drug therapy (136) 136
azacitidine - therapeutic use (134) 134
dose-response relationship, drug (134) 134
prospective studies (134) 134
methotrexate - therapeutic use (133) 133
lung neoplasms - drug therapy (130) 130
methotrexate - administration & dosage (130) 130
breast neoplasms - drug therapy (129) 129
child (120) 120
oncology, experimental (119) 119
medicine (118) 118
complications and side effects (117) 117
infusions, intravenous (117) 117
antimetabolites, antineoplastic - pharmacokinetics (115) 115
administration, oral (114) 114
diagnosis (114) 114
antineoplastic combined chemotherapy protocols - administration & dosage (113) 113
time factors (111) 111
neoplasms - drug therapy (110) 110
myelodysplastic syndromes - drug therapy (109) 109
research article (109) 109
antineoplastic agents - therapeutic use (108) 108
gastroenterology & hepatology (108) 108
disease progression (107) 107
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2232) 2232
Japanese (31) 31
French (9) 9
German (8) 8
Polish (8) 8
Spanish (8) 8
Italian (4) 4
Bulgarian (1) 1
Dutch (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood Cells, Molecules and Diseases, ISSN 1079-9796, 02/2013, Volume 50, Issue 2, pp. 119 - 130
This paper reviews the development of therapy for acute myelogenous leukemia that in 1973 led to the regimen of 7days of continuous intravenous... 
Anthracycline antibiotics | Acute myelogenous leukemia | Cytosine arabinoside | Chemotherapy | Daunorubicin | Antimetabolites | ACUTE GRANULOCYTIC-LEUKEMIA | CYTOSINE-ARABINOSIDE | TREATMENT SCHEDULES | DAUNOMYCIN | LA DAUNOMICINA | ACUTE MYELOID-LEUKEMIA | 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE | THERAPY | COMBINATION CHEMOTHERAPY | RUBIDOMYCIN | HEMATOLOGY | Cancer Care Facilities - history | Cyclophosphamide - administration & dosage | History, 21st Century | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Cyclophosphamide - isolation & purification | Cyclophosphamide - adverse effects | Child | Daunorubicin - administration & dosage | Hematology - history | History, 20th Century | Mercaptopurine - administration & dosage | Rats | Forecasting | Remission Induction | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Daunorubicin - history | Cyclophosphamide - history | Cyclophosphamide - pharmacology | Adolescent | Antineoplastic Combined Chemotherapy Protocols - history | Daunorubicin - isolation & purification | Mercaptopurine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - isolation & purification | Cytarabine - pharmacology | National Institutes of Health (U.S.) - history | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Daunorubicin - pharmacology | Cytarabine - adverse effects | Medical Oncology - history | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Case Management - history | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mercaptopurine - isolation & purification | France | Mercaptopurine - history | Mercaptopurine - adverse effects | Clinical Trials as Topic | Haplorhini | Animals | Cytarabine - history | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Dogs | Aged | Drug Screening Assays, Antitumor
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2017, Volume 92, Issue 7, pp. 599 - 606
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1125 - 1133
Summary Background Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on... 
Hematology, Oncology and Palliative Medicine | DOUBLE-BLIND | PROGNOSTIC-FACTORS | GENE | ONCOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vaccinia virus - genetics | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Cancer Vaccines - adverse effects | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Interleukin-2 - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucin-1 - immunology | Vaccines, Synthetic | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Mucin-1 - genetics | Index Medicus | Interleukin-2 | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Cancer Vaccines | Membrane Glycoproteins | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Mucin-1 | Vaccinia virus | Deoxycytidine | Antimetabolites, Antineoplastic | Cancer
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2013, Volume 88, Issue 11, pp. 961 - 966
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin,... 
PHASE-III TRIAL | SOUTHWEST-ONCOLOGY-GROUP | DOSE CYTOSINE-ARABINOSIDE | GROUP-B | ARA-C | DAUNORUBICIN | HEMATOLOGY | CANCER | CHEMOTHERAPY | MODULATION | INDUCTION TREATMENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Follow-Up Studies | Nausea - chemically induced | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Arabinonucleosides - administration & dosage | Idarubicin - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Idarubicin - administration & dosage | Adenine Nucleotides - administration & dosage | Idarubicin - therapeutic use | Drug Eruptions - etiology | Adenine Nucleotides - therapeutic use | Arabinonucleosides - adverse effects | Remission Induction | Arabinonucleosides - therapeutic use | Cytarabine - administration & dosage | Adenine Nucleotides - adverse effects | Induction Chemotherapy - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Pilot Projects | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Consolidation Chemotherapy - adverse effects | Anthracyclines | Index Medicus | AML | idarubicin | cytarabine | frontline therapy | clofarabine
Journal Article
Expert Opinion on Drug Safety, ISSN 1474-0338, 03/2009, Volume 8, Issue 2, pp. 191 - 202
Background: The syndrome of 5-fluorouracil (5-FU)-associated cardiotoxicity remains poorly defined. Patients and methods: We performed a literature review... 
capecitabine | cardiotoxicity | pancreatic cancer | angina | arrhythmia | colon cancer | fluoropyrimidines | myocardial infarction | breast cancer | 5-FU | Fluoropyrimidines | Myocardial infarction | Colon cancer | Arrhythmia | Capecitabine | Pancreatic cancer | Breast cancer | Angina | Cardiotoxicity | 5-FLUOROURACIL-INDUCED CORONARY VASOSPASM | RALTITREXED TOMUDEX | MYOCARDIAL-INFARCTION | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | CARDIAC TOXICITY | METASTATIC COLORECTAL-CANCER | FLUOROURACIL CARDIOTOXICITY | RANDOMIZED PHASE-III | ANGINA-PECTORIS | PHARMACOLOGY & PHARMACY | CONTINUOUS-INFUSION | Drug Administration Routes | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Vasodilator Agents - therapeutic use | Humans | Risk Factors | Calcium Channel Blockers - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Fluorouracil - administration & dosage | Cisplatin - therapeutic use | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Leucovorin - therapeutic use | Heart Diseases - drug therapy | Heart Diseases - chemically induced | Index Medicus
Journal Article
European Journal of Haematology, ISSN 0902-4441, 04/2004, Volume 72, Issue 4, pp. 292 - 295
: The optimal treatment of non‐Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy... 
first trimester | follicular lymphoma | safety | rituximab | pregnancy | Pregnancy | First trimester safety | Follicular lymphoma | Rituximab | B-CELL LYMPHOMA | ANTI-CD20 MONOCLONAL-ANTIBODY | NON-HODGKINS-LYMPHOMA | LOW-GRADE | CHOP CHEMOTHERAPY | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Antibodies, Monoclonal - adverse effects | Mitoguazone - administration & dosage | Antibodies, Monoclonal - therapeutic use | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pregnancy Trimester, First | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Pregnancy Complications, Neoplastic - drug therapy | Vincristine - administration & dosage | Adult | Female | Safety | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Etoposide - administration & dosage | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Antimetabolites, Antineoplastic - therapeutic use | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cladribine - therapeutic use | Methotrexate - administration & dosage | Peripheral Blood Stem Cell Transplantation | Pregnancy Outcome
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2016, Volume 34, Issue 5, pp. 636 - 642
Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of... 
Medicine & Public Health | Pancreatic cancer | S-1 | Intraperitoneal chemotherapy | Malignant ascites | Paclitaxel | Oncology | Peritoneal metastasis | Pharmacology/Toxicology | SURVIVAL | MONOTHERAPY | PERITONEAL CARCINOMATOSIS | OXALIPLATIN COMBINATION CHEMOTHERAPY | GEMCITABINE | TRIAL | THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | ADVANCED GASTRIC-CANCER | JAPAN | PHARMACOLOGY & PHARMACY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents, Phytogenic - administration & dosage | Deoxycytidine - therapeutic use | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - adverse effects | Tegafur - adverse effects | Tegafur - therapeutic use | Kaplan-Meier Estimate | Infusions, Parenteral | Paclitaxel - adverse effects | Treatment Outcome | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Oxonic Acid - adverse effects | Ascites - drug therapy | Disease-Free Survival | Administration, Intravenous | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Tegafur - administration & dosage | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations | Complications and side effects | Care and treatment | Chemotherapy | Usage | Research | Metastasis | Health aspects | Risk factors | Cancer | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2013, Volume 71, Issue 3, pp. 663 - 670
We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This... 
Medicine & Public Health | Capecitabine | Oncology | Cancer Research | Carcinoid | Temozolomide | Pharmacology/Toxicology | Neuroendocrine cancer | SURVIVAL | ISLET-CELL-CARCINOMA | DOXORUBICIN | PHASE-II | TUMOR-CELLS | DACARBAZINE | ENDOCRINE CARCINOMAS | STREPTOZOCIN | ONCOLOGY | PHARMACOLOGY & PHARMACY | MUTATIONS | ALKYLTRANSFERASE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Fluorouracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Female | Retrospective Studies | Liver Neoplasms - secondary | Neuroendocrine Tumors - pathology | Dacarbazine - administration & dosage | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Neuroendocrine Tumors - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Liver cancer | Chemotherapy | Pancreatic cancer | Development and progression | Metastasis | Antineoplastic agents | Health aspects | Cancer | Index Medicus
Journal Article